- Hydreight Technologies through its associated Medical network now offer Tirzepatide to Product Offering which also features GLP-1 Medications (Low-Cost Semaglutide), NAD+ and more
- Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
- Hydreight Partners with American Frontline Nurses with a Network of Over 26,000 Nurses
- Hydreight Partners with Ola Digital Health, an Independent, National Pharmacy Network to Provide Health and Wellness Services in Store
- Hydreight Founder and CEO, Shane Madden, Joins Founding Member Board of the American IV Association
- Hydreight to Participate in the Maxim Group Healthcare IT Conference January 24 – 25, 2024
- Hydreight Provides Year-End Review on Significant Growth and Progress
- Hydreight Adds Semaglutide to Product Offerings
- Hydreight Expands White Label Solution with a New National Wellness Med Spa Franchise
- Hydreight Reports Record Revenue in Q3 2023
More ▼
Key statistics
As of last trade, Hydreight Technologies Inc (NURS:CVE) traded at 0.26, 30.00% above the 52 week low of 0.20 set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.26 |
---|---|
High | 0.26 |
Low | 0.26 |
Bid | 0.255 |
Offer | 0.265 |
Previous close | 0.26 |
Average volume | 7.86k |
---|---|
Shares outstanding | 38.32m |
Free float | 12.16m |
P/E (TTM) | -- |
Market cap | 9.99m CAD |
EPS (TTM) | -0.0508 CAD |
Data delayed at least 15 minutes, as of May 23 2024 14:30 BST.
More ▼